Moderna Shot’s Covid Protection Stays Steady for Months_老虎社区_美港股上老虎

Moderna Shot’s Covid Protection Stays Steady for Months

Bloomberg2021-08-06

Vaccine maintains high efficacy for months after second dose Biotech’s quarterly earnings, sales top Wall Street estimates Moderna Inc. said its Covid-19 vaccine remained 93% effective through six ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

PekTS
·2021-08-06
Nice
回复
点赞
举报
Wanlin927
·2021-08-06
Nice
回复
3
举报
c86cecc
·2021-08-06
Ok
回复
1
举报
BBBBBBBBBB
·2021-08-06
Ok
回复
2
举报
edgetrader
·2021-08-06
I had this shot.
回复
3
举报
ARIESan
·2021-08-06
👏👏👍
回复
1
举报
收起
- MGOH:
  Good
  2021-08-06
  回复
  举报
Roticanai
·2021-08-06
Like
回复
1
举报
收起
- Mtan23:
  Good
  2021-08-06
  回复
  举报
CokeNBeer
·2021-08-06
Argh, should have taken this.
回复
2
举报
收起
- CokeNBeer:
  Sigh
  2021-08-06
  回复
  举报
Butt3rc00ki3
·2021-08-06
Like
回复
1
举报
收起
- MugenQiang:
  ok
  2021-08-06
  回复
  举报
edwinong
·2021-08-06
Like comment
回复
4
举报
收起
- Lawrence88:
  like
  2021-08-06
  回复
  举报
- BlackTechAI:
  pls help me comment with a smiley icon at my latest post today, go to my page thanks 😊
  2021-08-06
  回复
  举报
- edwinong:
  ok
  2021-08-06
  回复
  举报
Jenjorjack
·2021-08-06
Looks like vaccines are really strengthening people’s confidence and job vacancies are being taken up as free handouts coming to an endand economy is reopening. Please like comment and follow.
回复
2
举报
收起
- Tj23:
  Yes
  2021-08-06
  回复
  举报
- TkLm:
  Reopening of economy and vaccination rates go hand in hand.
  2021-08-06
  回复
  举报
987ce65
·2021-08-06
Awesome
回复
3
举报
收起
- Jenjorjack:
  Plrase help me like and comment thanks
  2021-08-06
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1183750069?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-06 09:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183750069","market":"us","top_or_hot":-1,"title":"Moderna Shot’s Covid Protection Stays Steady for Months","media":"Bloomberg","content":"<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","article_id":"1183750069","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","pubTimestamp":1628212078,"columns":[],"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"Moderna Shot的Covid保护几个月来保持稳定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":899787529,"gmtCreate":1628215607961,"gmtModify":1631891069187,"author":{"id":"3559435912098366","authorId":"3559435912098366","name":"PekTS","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3559435912098366","authorIdStr":"3559435912098366"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899787529","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899795653,"gmtCreate":1628214072072,"gmtModify":1633752550813,"author":{"id":"3582025117705198","authorId":"3582025117705198","name":"Wanlin927","avatar":"https://static.tigerbbs.com/8dcfce5bedd37636dfe4d9ca052f0f47","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582025117705198","authorIdStr":"3582025117705198"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899795653","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899705593,"gmtCreate":1628213594112,"gmtModify":1633752559150,"author":{"id":"3574926290820486","authorId":"3574926290820486","name":"c86cecc","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574926290820486","authorIdStr":"3574926290820486"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899705593","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899702977,"gmtCreate":1628213532499,"gmtModify":1633752560526,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899702977","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899473882,"gmtCreate":1628213011946,"gmtModify":1633752571678,"author":{"id":"3570751249933438","authorId":"3570751249933438","name":"edgetrader","avatar":"https://static.tigerbbs.com/7d0e920d94a7891f4c6393f3e5510ccc","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3570751249933438","authorIdStr":"3570751249933438"},"htmlText":"I had this shot.&nbsp;","listText":"I had this shot.&nbsp;","text":"I had this shot.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899473882","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899473323,"gmtCreate":1628213003362,"gmtModify":1633752571921,"author":{"id":"4087545408973980","authorId":"4087545408973980","name":"ARIESan","avatar":"https://static.tigerbbs.com/ab7b9364a4791173d66fbb5fda8ef925","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087545408973980","authorIdStr":"4087545408973980"},"htmlText":"👏👏👍","listText":"👏👏👍","text":"👏👏👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899473323","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5442365,"gmtCreate":1628215393958,"gmtModify":1635158816111,"authorId":3558490783279911,"author":{"id":3558490783279911,"idStr":"3558490783279911","authorId":3558490783279911,"name":"MGOH","avatar":"https://static.tigerbbs.com/a3985c9c508308ba1d202fb4e710894e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899473323,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":899470353,"gmtCreate":1628212929272,"gmtModify":1633752573301,"author":{"id":"3581913988119713","authorId":"3581913988119713","name":"Roticanai","avatar":"https://static.tigerbbs.com/4da10b7952b9a699e2c4703a67642740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581913988119713","authorIdStr":"3581913988119713"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899470353","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5441956,"gmtCreate":1628213280348,"gmtModify":1635158854814,"authorId":3579572647008782,"author":{"id":3579572647008782,"idStr":"3579572647008782","authorId":3579572647008782,"name":"Mtan23","avatar":"https://static.tigerbbs.com/21a2ddfc414d0d3eab50e895e776bf23","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899470353,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":899444309,"gmtCreate":1628212845601,"gmtModify":1631891547764,"author":{"id":"3581722811684208","authorId":"3581722811684208","name":"CokeNBeer","avatar":"https://static.tigerbbs.com/d83481d848bfcbe3dc2d701ebc1e6ce0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581722811684208","authorIdStr":"3581722811684208"},"htmlText":"Argh, should have taken this.","listText":"Argh, should have taken this.","text":"Argh, should have taken this.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899444309","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5441861,"gmtCreate":1628212856943,"gmtModify":1631891547766,"authorId":3581722811684208,"author":{"id":3581722811684208,"idStr":"3581722811684208","authorId":3581722811684208,"name":"CokeNBeer","avatar":"https://static.tigerbbs.com/d83481d848bfcbe3dc2d701ebc1e6ce0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899444309,"type":1,"supId":0,"prevId":0,"content":"Sigh","text":"Sigh","html":"Sigh"}],"langContent":"EN"},{"id":899446885,"gmtCreate":1628212731547,"gmtModify":1633752576810,"author":{"id":"3581548481060535","authorId":"3581548481060535","name":"Butt3rc00ki3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581548481060535","authorIdStr":"3581548481060535"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899446885","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5441860,"gmtCreate":1628212851577,"gmtModify":1635158864808,"authorId":3576130746722228,"author":{"id":3576130746722228,"idStr":"3576130746722228","authorId":3576130746722228,"name":"MugenQiang","avatar":"https://static.tigerbbs.com/f17ec4e89d68e2bc6ac39a336e9be71c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899446885,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":899440585,"gmtCreate":1628212476847,"gmtModify":1633752579890,"author":{"id":"3581723087274150","authorId":"3581723087274150","name":"edwinong","avatar":"https://static.tigerbbs.com/d42f3dae28f8c1740e66011b66f51ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581723087274150","authorIdStr":"3581723087274150"},"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/899440585","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5441801,"gmtCreate":1628212621538,"gmtModify":1635158869870,"authorId":3583102796843762,"author":{"id":3583102796843762,"idStr":"3583102796843762","authorId":3583102796843762,"name":"Lawrence88","avatar":"https://static.tigerbbs.com/c41c8eaaa633222579542cff942fc801","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899440585,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"},{"id":5443331,"gmtCreate":1628221319227,"gmtModify":1635158735067,"authorId":3577008494818778,"author":{"id":3577008494818778,"idStr":"3577008494818778","authorId":3577008494818778,"name":"BlackTechAI","avatar":"https://static.tigerbbs.com/d64102b43967a7880f608e7ec776385d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899440585,"type":1,"supId":0,"prevId":0,"content":"pls help me comment with a smiley icon at my latest post today, go to my page thanks 😊","text":"pls help me comment with a smiley icon at my latest post today, go to my page thanks 😊","html":"pls help me comment with a smiley icon at my latest post today, go to my page thanks 😊"},{"id":5443349,"gmtCreate":1628221405380,"gmtModify":1635158733478,"authorId":3581723087274150,"author":{"id":3581723087274150,"idStr":"3581723087274150","authorId":3581723087274150,"name":"edwinong","avatar":"https://static.tigerbbs.com/d42f3dae28f8c1740e66011b66f51ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899440585,"type":1,"supId":5443331,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":899440843,"gmtCreate":1628212456782,"gmtModify":1633752580235,"author":{"id":"3554873215379647","authorId":"3554873215379647","name":"Jenjorjack","avatar":"https://static.tigerbbs.com/d9d4687aa5519f0d2fb1b18f916be861","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3554873215379647","authorIdStr":"3554873215379647"},"htmlText":"Looks like vaccines are really strengthening people’s confidence and job vacancies are being taken up as free handouts coming to an endand economy is reopening. Please like comment and follow.","listText":"Looks like vaccines are really strengthening people’s confidence and job vacancies are being taken up as free handouts coming to an endand economy is reopening. Please like comment and follow.","text":"Looks like vaccines are really strengthening people’s confidence and job vacancies are being taken up as free handouts coming to an endand economy is reopening. Please like comment and follow.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/899440843","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5441875,"gmtCreate":1628212938612,"gmtModify":1635158863368,"authorId":3571780042589602,"author":{"id":3571780042589602,"idStr":"3571780042589602","authorId":3571780042589602,"name":"Tj23","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899440843,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"},{"id":5442144,"gmtCreate":1628214155370,"gmtModify":1635158836698,"authorId":3562811381335198,"author":{"id":3562811381335198,"idStr":"3562811381335198","authorId":3562811381335198,"name":"TkLm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899440843,"type":1,"supId":0,"prevId":0,"content":"Reopening of economy and vaccination rates go hand in hand.","text":"Reopening of economy and vaccination rates go hand in hand.","html":"Reopening of economy and vaccination rates go hand in hand."}],"langContent":"EN"},{"id":899456031,"gmtCreate":1628212212023,"gmtModify":1633752584555,"author":{"id":"3582709856792743","authorId":"3582709856792743","name":"987ce65","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582709856792743","authorIdStr":"3582709856792743"},"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899456031","repostId":1183750069,"repostType":4,"repost":{"id":"1183750069","kind":"news","pubTimestamp":1628212078,"share":"https://www.laohu8.com/m/news/1183750069?lang=&edition=full","pubTime":"2021-08-06 09:07","market":"us","language":"en","title":"Moderna Shot’s Covid Protection Stays Steady for Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1183750069","media":"Bloomberg","summary":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top","content":"<ul>\n <li>Vaccine maintains high efficacy for months after second dose</li>\n <li>Biotech’s quarterly earnings, sales top Wall Street estimates</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.</p>\n<p>A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.</p>\n<p>Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.</p>\n<p>“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.</p>\n<p>Amid concern over waning protection, some countries have already begun to offer vulnerable people&nbsp;third-dose&nbsp;booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.</p>\n<p>The shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.</p>\n<p>Currently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.</p>\n<p>Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.</p>\n<p>In the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.</p>\n<p><b>Seeking Approval</b></p>\n<p>Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.</p>\n<p>The agency is already reviewing the submission for a rival messenger RNA vaccine from&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.</p>\n<p>Moderna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.</p>\n<p>The company&nbsp;said in the release&nbsp;it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.</p>\n<p><b>Seeking Deals</b></p>\n<p>Moderna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.</p>\n<p>Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&amp;P 500 last month and is the index’s best performer this calendar year.</p>\n<p>As the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a&nbsp;presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.</p>\n<p>Moderna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson &amp; Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.</p>\n<p>“We’re just getting started,” Bancel said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shot’s Covid Protection Stays Steady for Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shot’s Covid Protection Stays Steady for Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/moderna-shot-s-protection-against-covid-stays-steady-for-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183750069","content_text":"Vaccine maintains high efficacy for months after second dose\nBiotech’s quarterly earnings, sales top Wall Street estimates\n\nModerna Inc. said its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.\nA final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.\nStill, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.\n“We believe a booster dose is likely to be necessary this fall, particularly in the face of the delta variant,” President Stephen Hoge said. Henotedthat the company must still determine the appropriate dosage of the third-shot before approaching U.S. regulators.\nAmid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization Director-General Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.\nThe shares rose 2.8% as of 9:55 a.m. in New York on Thursday. Covid vaccine-maker Pfizer Inc. lost 0.6%, while its partner BioNTech SE, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.\nCurrently, all three of the company’s booster candidates produced “robust antibody responses” against delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.\nDespite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.\nIn the “longterm endemic market,” Hoge said a multivalent shot that immunizes against multiple strains of the coronavirus is going to be the best way forward.\nSeeking Approval\nCambridge, Massachusetts-based Moderna also said it expected to complete its submission for full U.S. Food and Drug Administration approval for its vaccine this month.\nThe agency is already reviewing the submission for a rival messenger RNA vaccine from Pfizer Inc. and BioNTech SE, and is under growing pressure to complete the process quickly. With the delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.\nModerna, which reported its first profit earlier this year, had net income of almost $2.8 billion in the quarter ending June 30 on revenue of $4.4 billion, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.\nThe company said in the release it has signed $20 billion worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2 billion it announced in May. For 2022, it already has signed agreements for $12 billion in vaccine sales with options for $8 billion more. Moderna didn’t increase its forecast that it will produce 800 million to 1 billion Covid vaccine doses this year.\nSeeking Deals\nModerna’s views for total sales of its Covid vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. Last month, Pfizer boosted its vaccine sales forecast for 2021 to $33.5 billion.\nModerna’s shares have quadrupled since the beginning of the year, and the company hit $100 billion in market value for the first time July 14. The stock was made part of the S&P 500 last month and is the index’s best performer this calendar year.\nAs the biotech seeks to grow further, it will look opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12 billion in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. Chief Executive Officer Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.\nModerna has also built out its suite of leaders to double down on its commercial franchise. In the last quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.\n“We’re just getting started,” Bancel said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5441781,"gmtCreate":1628212472346,"gmtModify":1635158871835,"authorId":3554873215379647,"author":{"id":3554873215379647,"idStr":"3554873215379647","authorId":3554873215379647,"name":"Jenjorjack","avatar":"https://static.tigerbbs.com/d9d4687aa5519f0d2fb1b18f916be861","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899456031,"type":1,"supId":0,"prevId":0,"content":"Plrase help me like and comment thanks","text":"Plrase help me like and comment thanks","html":"Plrase help me like and comment thanks"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":88,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}